INTRODUCTION
The NY-ESO-1 human tumor antigen was recently identified using serological analysis of tumor antigens by recombinant cDNA expression (SEREX) cloning analysis of a human esophageal cancer (1) . It is a M r 22,000 cytoplasmic protein (180 amino acids; Ref.
2) expressed in a number of different tumor types including melanoma (reviewed in Ref. 3) . NY-ESO-1 belongs to the "cancer-testis" antigens (3), whose expression is restricted to a proportion of human cancer types as well as to germ cells of the testes and/or ovaries in healthy individuals and the trophoblast (3) but is not found in other normal tissues. In contrast to other known cancer-associated antigens, humoral responses against NY-ESO-1 are frequently observed in patients with NY-ESO-1-expressing tumors (4) . CD8 ϩ T-cell epitopes derived from cancer-testis antigens, have shown considerable promise in cancer immunotherapy (5) . At least four CD8 ϩ T-cell epitopes for NY-ESO-1 have now been described for the MHC-class I allele, HLA-A2. These include, SLLMWITQCFL 157-167 , SLLM-WITQC 157-165 , QLSLLMWIT [155] [156] [157] [158] [159] [160] [161] [162] [163] , and the recently identified cryptic epitope, LMWITQCFL 159 -167 (6 -8) . Although SLLMWITQCFL 157-167 , SLLMWITQC [157] [158] [159] [160] [161] [162] [163] [164] [165] , and LM-WITQCFL 159 -167 exhibit good in vitro immunogenicity, the cryptic LMWITQCFL 159 -167 peptide does not appear to be naturally processed (9) . Furthermore, QLSLLMWIT 155-163 is poorly immunogenic and CD8
ϩ CTLs recognizing this epitope are rarely detected in cancer patients (6 -8) . Although a poorer binder for HLA-A*0201 than the SLLM-WITQCFL 157-167 and QLSLLMWIT [155] [156] [157] [158] [159] [160] [161] [162] [163] peptides, the SLLMWITQC 157-165 peptide is very efficiently recognized by CD8 ϩ T cells from HLA-A*0201 melanoma patients (9 -11) . Furthermore, vaccination of NY-ESO-1 ϩ cancer patients with SLLMWITQCFL 157-167 and SLLMWITQC [157] [158] [159] [160] [161] [162] [163] [164] [165] peptides induced NY-ESO-1-specific CD8 ϩ T cells, some stabilization of disease, and regression of individual metastases in some patients (12) . The demonstration that CD8 ϩ T cells can provide potent anticancer activity has resulted in a substantial number of human cancer vaccine trials aiming to induce anticancer CD8 ϩ T cells. However, the importance of antitumor CD4 ϩ T-cell responses for efficient activation and maintenance of anticancer CD8 ϩ T cells has been established in several studies (13) (14) (15) . In this regard, an NY-ESO-1 epitope restricted to the MHC class II allele, HLA-DPB1*0401-0402 (found in 43-70% of Caucasians), has been identified (SLLMWITQCFLPVF [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] ) and overlaps the SLLMWITQCFL 157-167 and SLLMWITQC [157] [158] [159] [160] [161] [162] [163] [164] [165] epitopes (16) . Furthermore, another HLA-DRB1*0401-restricted CD4 epitope has recently been identified and localizes to NY-ESO-1 119 -143 (17, 18) . Thus, the major advantage of using a full-length tumor protein as a vaccine is the possibility of generating multiple MHC class I and IIrestricted T-cell responses, rather than with peptide vaccines, which limit CD8 ϩ T-cell responses to only one of six possible MHC class-I alleles (i.e., HLA-A2).
Currently, there are few vaccine modalities that safely and effectively induce potent CD8
ϩ T-cell responses in humans with few adjuvants approved for human use. The use of in vitro-generated, autologous dendritic cells (DCs) as cellular adjuvants for vaccine delivery is being widely tested in cancer patients (19, 20) . However, considerable research is required to optimize the preparation, antigen loading, and route of delivery of DC-based cancer vaccines to achieve broad clinical utility (20) . The ISCOMATRIX adjuvant (an immunostimulatory complex that does not contain antigen) is a cage-like structure, typically 40 nm, composed of saponin, phospholipid, and cholesterol. An ISCOMATRIX vaccine (an immunostimulatory complex that contains antigen) can be generated by associating the antigen with the ISCOMATRIX adjuvant. ISCOMATRIXbased vaccines have been used safely in humans to induce strong antibody responses as well as potent CD4
ϩ T-helper-cell and CD8
ϩ CTL responses to several viral and cancer antigens (21) (22) (23) . ISCOMATRIX vaccines have a number of potential advantages for use in cancer immunotherapy. These include (a) the absence of potential safety issues associated with live vector systems and DNA; (b) the ability for repeated use due to the lack of induction of neutralizing antibody responses; (c) the induction of effective CD8 ϩ T-cell responses, even in the presence of antibodies specific for the vaccine antigen (24); and (d) the generation of broad MHC class I and II epitopes when used with full-length protein antigen resulting in more robust and sustainable immune responses.
Here we illustrate, in human tissue culture and murine in vivo models, the immunogenicity of a NY-ESO-1 vaccine composed of full-length NY-ESO-1 protein combined with ISCO-MATRIX adjuvant. In addition, we show that the NY-ESO-1 vaccine generates both humoral and T-cell responses and, therefore, represents a valuable therapeutic anticancer vaccine.
MATERIALS AND METHODS
Preparation of Recombinant NY-ESO-1 Protein. The expression plasmid pLICR100kan was transfected into Escherchia coli B strain B21, which was fermented to produce NY-ESO-1 as an insoluble inclusion body. Cells were disrupted using high-pressure homogenization, and inclusion bodies were isolated and solubilized using denaturant. The purification of NY-ESO-1 used a three-step column chromatography process of immobilized metal affinity, anion exchange, and hydrophobic interaction chromatography using Chelating Sepharose FF, QSepharose FF, and Phenyl Sepharose FF (Pharmacia Biotech, Uppsala, Sweden), respectively.
5
Preparation of ISCOMATRIX Adjuvant. ISCOMA-TRIX adjuvant was prepared as described previously (25) , but using ultrafiltration instead of dialysis. Briefly, a purified fraction of Quillaia saponin (ISCOPREP saponin; CSL Limited, Parkville, VIC, Australia) at 100 mg/ml was added to a solution of 10 mg/ml cholesterol (Sigma, St. Louis, MO) and 10 mg/ml dipalmitoylphosphatidylcholine (Avanti Polar Lipids, Alabaster, AL) dissolved in 20% w/v MEGA-10 (Sigma) and buffered isotonic saline (pH 6.2) to give a final concentration of 4 mg/ml ISCOPREP saponin and 0.8 mg/ml of cholesterol and buffered isotonic saline. The solution was then held at 25°C for 60 min and diluted a further 1 in 4 with buffered isotonic saline (pH 6.2). During the subsequent ultrafiltration against 14 volumes of buffered isotonic saline (pH 6.2), ISCOMATRIX adjuvant containing ISCOPREP saponin, cholesterol, and buffered isotonic saline was formed.
Preparation and Characterization of NY-ESO-1 Vaccine. NY-ESO-1 vaccine was prepared by mixing recombinant NY-ESO-1 protein (0.4 mg/ml) with ISCOMATRIX adjuvant (0.4 mg/ml ISCOPREP) at a 1:1 ratio in 0.5 M phosphate buffer containing 0.75 M NaCl, 0.25 M glycine, and 0.2 M urea (pH 6.5). The concentration of ISCOPREP saponin was determined by reversed-phase high-performance liquid chromatography, and the concentration of protein was determined by amino acid analysis. Association between NY-ESO-1 and ISCOMATRIX adjuvant was confirmed by flow cytometry using a FACSCalibur equipped with CELLQuest software (Becton Dickinson, San Jose, CA). Briefly, NY-ESO-1 vaccine was double labeled using a FITC-conjugated anti-NY-ESO-1 monoclonal antibody (mAb; ES121; Ref. 26) and a biotinylated-anti-ISCOMATRIX adjuvant mAb (CSL Limited) followed by streptavidin-allophycocyanin (APC) (PharMingen/Becton Dickinson, San Jose, CA). The formulation was also analyzed by scanning electron microscopy, and the particle size was analyzed by dynamic light scattering using a Nicomp 370. The batch-to-batch variability of the NY-ESO-1 vaccine aggregate profile is relatively consistent as assessed by both screening electron microscopy and fluorescence-activated cell sorting (FACS) analysis.
IHC Analysis of NY-ESO-1 Expression in Tumor Cell Lines. Immunohistochemistry (IHC) for NY-ESO-1 expression was performed on human tumor biopsy samples and transfected tumor cell lines using the mouse-antihuman-NY-ESO-1 mAb, E978 (3 g/ml), as described previously (26) . IHC was performed using the Vectastain Elite Universal ABC kit purchased from Vector Laboratories (Burlingame, CA). All of the sections were submitted to 3% H 2 O 2 /PBS for 10 min to block endogeneous peroxidase. Endogeneous biotin activity was quenched by sequential application of egg white and skim milk.
All of the incubations were performed at room temperature using the Shandon Sequenza immunostainer. 3-Amino-9-ethylcarbazole (Sigma A-5754) was used as the chromogen, and slides were counterstained with Mayer's hematoxylin (Amber Scientific MH-5L). Application of CrystalMount (Biomeda M03) preceded dehydration and mounting in DePeX (BDH 36125).
Quantitative Real-Time PCR Analysis of NY-ESO-1 Expression on Tumor Cell Lines. To quantify the copy number of NY-ESO-1 mRNA, quantitative real-time PCR was performed using ABI Prism 7700 Sequence Detection System Taqman (Applied Biosystems, Foster City, CA). A multiplex PCR containing 1 l cDNA was set up with the housekeeping gene ␤-actin according to the manufacturer's instructions (Applied Biosystems) to normalize the cDNA samples. Probes and primers for NY-ESO-1 were designed across intron/exon boundaries to avoid amplification of genomic DNA. The primer and probe sequences were as follows: forward, 5Ј-TGC TTG AGT TCT ACC TCG CCA T-3Ј; reverse, 5Ј-TAT GTT GCC GGA CAC AGT GAA-3; Probe, 6FAM-AGG ATG CCC CAC CGC TTC CC-TAMRA. The conditions used are described by Taqman protocols (Applied Biosystems) with up to 40 cycles of amplification used per sample. Results were analyzed using the SDS program version v1.7. Copy numbers of NY-ESO-1 were calculated from standard curves of the relevant plasmid and were expressed per 10 5 copies of the housekeeping gene ␤-actin in 100 ng of total RNA. [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] (HLA-DP4-restricted; 10 g/ml, 2 h at room temperature), were washed twice in RPMI 1640, and were cocultured with equal numbers of nonirradiated PBMCs in 0.5 ml of Iscove's modified Dulbecco's medium supplemented with 5% human serum (CSL Limited) in 48-well plates. At day 3 of the culture, 5 units/ml interleukin (IL)-2 (Peprotech, Rocky Hill, NJ) were added. After 7 days, the T cells were restimulated with irradiated, peptide-pulsed, autologous PBMCs and were maintained in the presence of 25 units/ml IL-2 in 24-well plates. Thereafter, the CD8 ϩ T-cell line (1 ϫ 10 5 cells) was restimulated weekly with 1 ϫ 10 4 peptide-pulsed, irradiated (10, 3 ), 2 h at room temperature] and were blocked for 1 h with PBS supplemented with 10% FCS. Peptidesensitized (10 g/ml, 2 h at room temperature and washed) T2 cells or melanoma target cells (5,000/well) were cocultured with 1.5 ϫ 10 3 CD8 ϩ T cells specific for the NY-ESO-1 SLLM-WITQC 157-165 peptide. T2 cells, pulsed with an irrelevant HLA-A2-restricted peptide (MAGE-3:-FLWGPRALV 271-279 ), were used as a negative control. The LAR (Ludwig Austin Repatriation) series of melanoma cell lines were derived at the Ludwig Institute from patients' biopsy samples, and consent was obtained from each patient before establishment. After overnight culture, cells were lysed with H 2 O for 30 min; and horse-radish-peroxidase-labeled anti-IFN-␥ antibody was added for 2 h (10 g/ml PBS, 3% FCS, and 0.05% Tween 20). After washing, spots were developed with 3-amino-9-ethyl-carbazole in acetate buffer for 8 min. The plates were washed with H 2 0 and air-dried. IFN-␥-spots were counted using a video camera (TK-1280E, Zeiss, Göttingen, Germany) and the VideoPro software (Olympus, Mount Waverly, Australia).
Uptake of NY-ESO-1 Vaccine by MoDCs and Induction of Maturation. Monocyte-derived DCs (MoDCs) were generated by affinity-purifying CD14
ϩ monocytes from healthy donor PBMC buffy packs (Red Cross Blood Bank, Melbourne, VIC, Australia) using the MACS CD14 isolation kit (Miltenyi Biotech, Sunnyvale, CA). The monocytes (5 ϫ 10 5 /well) were cultured in 1 ml of RPMI 1640 supplemented with 10% FCS, granulocyte macrophage colony-stimulating factor (40 ng/ml; Schering-Plough, Sydney, NSW, Australia) and IL-4 (500 units/ ml; Schering-Plough, Kenilworth, NJ) in 24-well plates. On day 7, MoDCs represented Ͼ90% of cultured cells as determined by CD1a and HLA-DR expression using FACS analysis. At day 7, all of the wells were pooled and the cell concentration readjusted to 1 ϫ 10 5 cells/ml. DCs were incubated with NY-ESO-1 vaccine (10 g/ml ISCOPREP saponin) for 1 h at 37°C, were washed thoroughly, and were recultured prior to analysis for uptake. Uptake of NY-ESO-1 vaccine by MoDCs was assessed by flow cytometry using a FITC-conjugated anti-NY-ESO-1 mAb (clone ES121) and a biotinylated-anti-ISCOMATRIX adjuvant mAb (clone 703B) followed by streptavidin-APC (PharMingen/Becton Dickinson, San Jose, CA). Isotypematched control antibodies were used to ensure specificity of antibody binding. In a separate series of experiments, one-half of the NY-ESO-1 vaccine-pulsed MoDC cultures were matured overnight (18 h) with various classes of stimuli. These included pro-inflammatory mediators: tumor necrosis factor (TNF)-␣ (10 ng/ml; R&D systems, Minneapolis, MN); IFN-␣2a (1000 units/ ml; Roferon-A, Roche Products Pty., Sydney, NSW, Australia); prostaglandin E 2 (PGE 2 ) (1 M final concentration; ICN Biomedicals, Aurora, OH); or CD40L-trimer (1 g/ml; gift from Immunex Corp, an Amgen subsidiary, Seattle, WA); or intact E. coli (grown at log phase and used at 5.2 ϫ 10 6 E. coli/ml). The nonmatured MoDCs were kept in their culture medium before analysis for phenotypic maturation. Flow cytometric analysis of MoDCs was performed using the following mAbs: FITC- In separate experiments, MoDCs were pulsed with NY-ESO-1 vaccine (20 g/ml ISCOPREP saponin), were washed thoroughly, and then were matured overnight by culturing in fresh medium containing granulocyte macrophage colony-stimulating factor (40 ng/ml), IL-4 (500 units/ml), TNF-␣ (10 ng/ ml), IFN-␣2a (1000 units/ml), and PGE 2 (1 M/ml). These MoDCs were then cocultured with either an NY-ESO-1 SLLM-WITQCFLPVF 157-170 -specific CD4 ϩ T-cell line (HLA-DP4-restricted) or an NY-ESO-1 SLLMWITQC 156 -165 -specific CD8 ϩ T-cell line (HLA-A2-restricted) for 4 h, and peptideinduced secretion of IFN-␥ by CD4 ϩ or CD8 ϩ T cells was assessed by intracellular cytokine secretion assay using FACS. For the CD8 ϩ T-cell assays, several controls were included during the analysis. Cytokine-matured MoDCs (not pulsed with NY-ESO-1 vaccine) were pulsed with either NY-ESO-1 SLLM-WITQC 157-165 peptide (positive control) or the MAGE-3-HLA-A2-restricted peptide (FLWGPRALV 271-279 ; negative control) and were cocultured with the NY-ESO-1 SLLMWITQC 157-165 -specific CD8
ϩ CTL cell line in parallel. As additional controls, transporter associated with antigen processing (TAP)-deficient, HLA-A2 ϩ , T2 cells were pulsed with NY-ESO-1 vaccine and used as APC to eliminate the possibility that NY-ESO-1 vaccine contained or generated free NY-ESO-1 SLLMWITQC 156 -165 peptides during the assay period.
Mice. Female BALB/c and C57BL/6 mice were purchased from Animal Resource Centre (Perth, Australia) and were used at 8 -12 weeks of age. Transgenic HHD mice have a transgene composed of the ␣1 and ␣2 domains of HLA-A2 linked to the ␣3, trans-membrane and cytoplasmic domains of H-2D b , with the ␣1 domain linked to human ␤ 2 -microglobulin. This transgene was introduced into murine ␤ 2 -microglobulin and H-2D b double knockout mice; thus, the only MHC expressed by the HHD mouse was the modified HLA-A2 molecule (27) . HHD mice were bred at the Queensland Institute for Medical Research and were used at 8 -12 weeks of age.
Immunization and CD8 ؉ T-cell Assays Using HHD Mice. Five mice/group were immunized s.c. with 100 l into the scruff of the neck with the NY-ESO-1 vaccine (5 g of both NY-ESO-1 and ISCOPREP saponin), or with NY-ESO-1 protein (5 g of protein) or with the ISCOMATRIX adjuvant (5 g of ISCOPREP saponin). Three weeks after immunization, splenocytes isolated from individual mice were separately restimulated with peptide-pulsed (10 g/ml, 37°C, 1 h, two washes) and irradiated (3000 rad) lipopolysaccharide blasts (effector:stimulator ratio, 3:1), as described previously (28) . On day 6, cultures were used as effectors in standard enzyme-linked immunospot assays (29) and/or 51 Cr-release assays using EL4 HHD target cells (28) sensitized with NY-ESO-1 peptides. Some cultures were subject to two additional rounds of weekly restimulation with SLLMWITQC 157-165 -sensitized irradiated (8000 rad) HHD EL4 cells (effector:stimulator ratio, 15:1) before use as effectors against human melanoma cell line targets. The human tumor cell lines were SK-Mel-37 (30), A11-1c, A05, A09-M, A02-Mb, and A12-M, which were derived from patients enrolled in a therapeutic clinical trial (31) .
Antibody and IFN-␥ Responses in BALB/C Mice. Mice were immunized s.c. with 100 l into the scruff of the neck, twice, 3 weeks apart, with the NY-ESO-1 vaccine (5 g of NY-ESO-1 and ISCOPREP saponin), or with NY-ESO-1 protein (5 g of protein), or with the ISCOMATRIX adjuvant (5 g of ISCOPREP saponin). Immediately before, and 7 days after, the second immunization, serum was collected for antibody determination, and spleen cells were collected for the measurement of IFN-␥ secretion. Antibody to recombinant NY-ESO-1 was assayed by a standard indirect enzyme immunoassay. Plates were coated by overnight incubation with 10 g/ml NY-ESO-1 protein followed by blocking in PBS containing 1% casein. Sera were tested at 5-fold dilutions starting from 1:100. The plates were incubated with horseradish peroxidase-conjugated antimouse IgG (KPL, Gaithersburg, MD) followed by the addition of tetramethylbenzidine substrate solution (KPL). The reaction was stopped by the addition of H 2 SO 4 , and the absorbance was read at 450 nm. Titers were determined from a standard curve generated on each plate using four-parameter fit calculations (KCJr; Bio-Tek Instruments, Winooski, VT).
Spleen-cell-derived IFN-␥ was assayed in supernatants from in vitro-stimulated splenocyte cultures from immunized BALB/c mice (n ϭ 3/group). Splenocytes (0.5 ϫ 10 6 /well) were cultured in 96-well plates (Costar, Cambridge, MA), together with 2.5 g/ml of recombinant NY-ESO-1 protein for 72 h at 37°C and 5% CO 2 in RPMI 1640 supplemented with 5% v/v inactivated FCS (CSL Limited), 5 ϫ 10 Ϫ5 M 2-mercaptoethanol (Life Technologies, Inc., Inc. Rockville, MD), and 40 g/ml gentamicin (CSL Limited Australia). Plates were coated by overnight incubation with rat-antimouse IFN-␥ (Endogen, Woburn, MA) and blocked with 1% casein in PBS. Cell culture supernatants were tested in triplicate at a 1:10 dilution using recombinant purified IFN-␥ (Sigma) as a standard. The plates were then incubated with biotinylated rat antimouse IFN-␥ followed by streptavidinhorseradish peroxidase (Amersham Pharmacia Biotech Ltd, Little Chalfont, Bucks, United Kingdom) and were developed with tetramethylbenzidine substrate (KPL). The reaction was stopped by the addition of H 2 SO 4 , and the absorbance at 450 nm was determined. IFN-␥ concentrations were determined from a standard curve generated on each plate using fourparameter-fit calculations (KCJr; Bio-Tek Instruments).
B16-NY-ESO-1 Tumor Challenge. B16 melanoma cells were transfected using electroporation with the mammalian expression plasmid, pCDNA3, encoding the cDNA for NY-ESO-1 (Invitrogen, Carlsbad, CA). Selection with G418 (800 g/ml) and limit-dilution cloning yielded a clone expressing NY-ESO-1 (B16-NY-ESO-1) as determined by IHC and quantitative real-time PCR. C57BL/6 mice (n ϭ 6/group) were vaccinated twice (at 0 and 4 weeks) with the NY-ESO-1 vaccine, or with the ISCOMATRIX adjuvant alone as a control. Four weeks after the second immunization, mice were challenged with B16-NY-ESO-1. The tumor cells (1 ϫ 10 4 ) were injected s.c. on the back, and tumor volume was measured over time. Mice were euthanized when tumors reached Ͼ180 mm 2 .
RESULTS

Characterization of the NY-ESO-1 Vaccine Formulation. Efficient induction of CD8
ϩ T-cell responses by ISCO-MATRIX adjuvant is believed to require association of the antigen and the adjuvant. As a result, a number of strategies to achieve this have been developed (29) . In this case, simple mixing of ISCOMATRIX adjuvant with recombinant NY-ESO-1 protein appeared to be sufficient to ensure adequate association between the vaccine components, presumably because the positively charged NH 2 terminus of the NY-ESO-1 protein (1) could interact with the negatively charged ISCOMA-TRIX adjuvant via electrostatic interactions. Association for the two components (i.e., NY-ESO-1 and ISCOMATRIX adjuvant) could be demonstrated by FACS analysis, with 94% of FACSdetectable vaccine material stained positive for both NY-ESO-1 (anti-NY-ESO-1 mAb, ES121) and ISCOMATRIX adjuvant (anti-ISCOMATRIX adjuvant mAb, 706B; Fig. 1A ). ISCOMA-TRIX adjuvant is typically 40 nm in size and, thus, not readily detectable by FACS. However, as shown in Fig. 1B , the majority of the NY-ESO-1 vaccine formulation was composed of large aggregates of NY-ESO-1 vaccine that were ϳ1-2 M in size. There were also some larger aggregates present but they represented a minority of the NY-ESO-1 vaccine and likely act in the same manner as the smaller aggregates. These data illustrate that NY-ESO-1 had effectively associated with ISCO-MATRIX adjuvant and resulted in the formation of aggregates.
NY-ESO-1 Vaccine Is Taken Up by Human MoDCs but Does Not Induce DC Maturation. DCs can be efficiently generated from CD14 ϩ blood monocytes (MoDCs) after 6 -7 days of culture in granulocyte macrophage colony-stimulating factor and IL-4 (19, 20) . These DCs were phenotypically immature, expressing intermediate levels of MHC class II molecules and low levels of CD80, CD83, and CD86 (19, 20) . We examined whether immature MoDCs could ingest the NY-ESO-1 vaccine and whether uptake of the NY-ESO-1 vaccine was sufficient to induce the phenotypic maturation of immature MoDCs in vitro. Immature MoDCs were incubated with the NY-ESO-1 vaccine either at 4°C or at 37°C for 1-3 h. The cells were then washed and examined by FACS for surface detection of NY-ESO-1 vaccine using either the anti-NY-ESO-1 mAb (ES121; Fig. 2B ) or the anti-ISCOMATRIX mAb (A706; Fig. 2, C-D) . In parallel, MoDCs were permeabilized, and surface versus intracellular NY-ESO-1 or ISCOMATRIX adjuvant was examined by FACS (Fig. 2, D and F) . Firstly, the isotype-matched control mAb did not stain MoDCs pulsed with NY-ESO-1 vaccine (Fig. 2A) . Similarly, neither the anti-NY-ESO-1 mAb (ES121) nor the anti-ISCOMATRIX adjuvant mAb bound unpulsed MoDCs (data not shown). However, the NY-ESO-1 vaccine rapidly (1 h) and efficiently bound to the surface of MoDCs as detected by either anti-NY-ESO-1 mAb (Fig. 2B) or anti-ISCOMATRIX adjuvant mAb (Fig. 2C) , with between 36 and 43% of MoDCs binding detectable NY-ESO-1 or ISCOMATRIX adjuvant at the cell surface. Cell surface binding was temperature dependent, because the NY-ESO-1 vaccine was not detected when MoDCs were pulsed with the NY-ESO-1 vaccine at 4°C (data not shown). Intracellular staining after 1 h revealed that the majority of the NY-ESO-1 vaccine was bound to the cell surface; 90% of staining was detected on nonpermeabilized MoDCs (Fig. 2, B and  C) with an additional 5-10% staining appearing after cell permeabilization (Fig. 2D) . This suggests that, initially, the hydrophobic NY-ESO-1 vaccine is predominantly incorporated into the cell surface lipid membrane with only a small proportion of the NY-ESO-1 vaccine internalized. Detection of the NY-ESO-1 vaccine decreased at the cell surface by 3 h (28% at 3 h versus 43% at 1 h; Fig. 2, C and E) , with the majority of NY-ESO-1 vaccine detectable intracellularly at this time (42% at 3 h versus 49% at 1 h; Fig. 2, D and F) , suggesting progressive internalization of surfacebound NY-ESO-1 vaccine over time.
Interestingly, the NY-ESO-1 vaccine was a poor inducer of MoDC maturation in vitro, only marginally up-regulating HLA-DR and CD86 (Ͻ2-fold) but not CD80, CD83, or HLA-ABC (Table 1 ). This was in contrast to known inducers of MoDC maturation, such as CD40L, pro-inflammatory cytokines (TNF-␣, IFN-␣, and PGE 2 ), or intact E. coli, which all upregulated these maturation markers (Table 1; 32) .
MoDCs Pulsed with the NY-ESO-1 Vaccine Cross-Present the HLA-A2-Restricted Epitope NY-ESO-1 157-165 to Cytotoxic T Cells. The ability of human MoDCs to process captured NY-ESO-1 vaccine into HLA-A2-restricted peptides was next assessed using a short-term CD8 ϩ CTL line specific for the HLA-A2-restricted NY-ESO-1 peptide, SLLM-WITQC 157-165 . Immature HLA-A2
ϩ MoDCs were pulsed with the NY-ESO-1 vaccine for 1 h and were then either cultured for 4 h or 18 h in granulocyte macrophage colony-stimulating factor and IL-4 (immature) or matured with a cocktail of pro-inflammatory mediators (TNF-␣, IFN-␣, and PGE 2 ) for 4 h or 18 h before coculture with the CD8 ϩ CTL line. As specificity controls, immature MoDCs or those matured with the above cytokine mixture were pulsed with either the NY-ESO-1 peptide, SLLMWITQC 157-165 , or with the irrelevant HLA-A2-restricted MAGE-3 peptide, FLWGPRALV 271-279 (data not shown). Several observations were made. Firstly, in the absence of antigen, immature (Fig. 3A) or matured MoDCs (data not shown) were incapable of inducing IFN-␥ secretion in the peptide-specific CD8 ϩ CTL line, as determined by intracellular cytokine staining, but were as efficient as transporter associated with antigen processing (TAP)-deficient T2 cells at presenting pulsed-SLLMWITQC 157-165 peptide (Fig. 3, B and E) . Second, immature MoDCs were capable of processing the NY-ESO-1 vaccine into sufficient HLA-A2/SLLMWITQC 157-165 peptide complexes to induce intracellular IFN-␥ secretion by the CD8 ϩ CTL line (Fig. 3C) . Third, maturation of the NY-ESO-1 vaccinepulsed MoDCs with pro-inflammatory cytokines resulted in a significant increase (1.1 versus 4.7%) in the proportion of CD8 ϩ CTL secreting IFN-␥ (Fig. 3D) . This latter finding is consistent with the observation that the NY-ESO-1 vaccine was poor at inducing MoDC maturation in vitro (Table 1) and that DC activation is required for effective cross-presentation.
MoDCs, pulsed with the NY-ESO-1 vaccine, induced a lower proportion of SLLMWITQC 157-165 -specific CD8 ϩ CTLs to secrete IFN-␥ as compared with SLLMWITQC 157-165 -pulsed MoDCs. This likely reflects differences in the molar ratio of SLLMWITQC 157-165 peptide generated from a full-length protein that would be available for loading onto empty class I MHC in the endoplasmic reticulum (in the presence of other competing peptides), as compared with saturating levels of purified SLLMWITQC 157-165 peptide added externally. Furthermore, the response induced by MoDCs pulsed with the NY-ESO-1 vaccine was not due to free SLLMWITQC 157-165 peptide contaminating the NY-ESO-1 vaccine preparation (due to degradation products, and so forth), because the HLA-A2 ϩ transporter associated with antigen processing (TAP)-deficient T2 cell line was unable to present detectable SLLMWITQC 157-165 peptide when pulsed with NY-ESO-1 vaccine (Fig. 3F) . Finally, maturation for 4 h was as effective as for 18 h at optimizing the processing of the NY-ESO-1 vaccine into SLLMWITQC [157] [158] [159] [160] [161] [162] [163] [164] [165] peptide for detection by the CD8 ϩ CTL line (Fig. 3G) . These data illustrate that the NY-ESO-1 vaccine is effectively taken up and processed by human MoDCs but that, in vitro, these DCs require additional maturation for optimal presentation of MHC/ SLLMWITQC 157-165 peptide complexes to CD8
ϩ CTLs.
MoDCs Pulsed with the NY-ESO-1 Vaccine Present T-Helper-Cell Epitopes from NY-ESO-1 via MHC class II
Molecules. The NY-ESO-1 epitope, SLLMWITQCFLP-VF 157-170 , is restricted to the MHC class II allele HLA- DPB1*0401-0402 (found in 43-70% of Caucasians). To assess presentation of the NY-ESO-1 vaccine to class II-restricted CD4 ϩ T cells, immature HLA-DP4 ϩ MoDCs were pulsed with the NY-ESO-1 vaccine for 1 h and then were cultured in the absence or presence of pro-inflammatory mediators (TNF-␣ ϩ IFN-␣ ϩ PGE 2 ) for 18 h before coculture with the NY-ESO-1 157-170 peptide-specific CD4 ϩ T-cell line. As shown in Fig. 4 , only low levels of IFN-␥ were produced by the CD4 ϩ T cells cocultured with MoDCs in the absence of antigen, whereas DCs pulsed with the NY-ESO-1 vaccine were as efficient at presenting the SLLMWITQCFLPVF 157-170 epitope to CD4 ϩ T cells as were SLLMWITQCFLPVF 157-170 peptide-pulsed DCs (Fig. 4,  B and C) . Furthermore, DC maturation did not enhance the presentation of the SLLMWITQCFLPVF 157-170 epitope by the NY-ESO-1 vaccine-pulsed MoDCs; that presentation was already optimal in immature cells (Fig. 4, C and D) . Therefore, presentation of MHC class II-restricted epitopes from NY-ESO-1 by MoDCs is highly efficient.
IFN-␥-Biased Responses in BALB/c Mice Vaccinated with the NY-ESO-1 Vaccine.
The ability of anticancer vaccines to induce IFN-␥-secreting T cells appears to be critical to their effectiveness. Such T cells also increase the levels of the IFN-␥-regulated IgG isotype, IgG2a, in mice. To assess whether the NY-ESO-1 vaccine induced IFN-␥-biased antibody responses, BALB/c mice were vaccinated with either NY-ESO-1 protein alone or the NY-ESO-1 vaccine, and NY-ESO-1specific antibody responses were examined. Immunization with the NY-ESO-1 vaccine induced significantly higher serum levels of NY-ESO-1-specific IgG1 (8-fold) and dramatically increased IgG2a (300-fold; P Ͻ 0.01) above that seen in BALB/c mice immunized with NY-ESO-1 protein alone (Fig. 5A) . The increased titer of NY-ESO-1-specific IgG2a in mice immunized with NY-ESO-1 vaccine correlated with a 3-8-fold increase in IFN-␥-secreting spleen cells in vitro as compared with mice immunized with NY-ESO-1 protein alone (Fig. 5B ). Thus, the high level of NY-ESO-1-specific IgG2a-and IFN-␥-producing spleen cells suggested the efficient induction of IFN-␥-biased immune responses by the NY-ESO-1 vaccine. 
HLA-A2 Transgenic (HHD) Mice Treated with the NY-ESO-1 Vaccine Generate NY-ESO-1-Specific CD8
؉ CTLs in Vivo. To determine whether the NY-ESO-1 vaccine could generate HLA-A2-restricted epitopes in vivo (epitopes relevant to the human system), HHD HLA-A2 transgenic mice were vaccinated with the NY-ESO-1 vaccine. Spleen cells were isolated after 3 weeks and restimulated for 6 days with irradiated lipopolysaccharide blasts pulsed with HLA-A2-restricted, NY-ESO-1-specific peptides. Fig. 6A shows that HHD mice vaccinated with the NY-ESO-1 vaccine generated CD8 ϩ T-cell responses that recognized the NY-ESO-1 peptide SLLMWITQC 157-165 and to a lesser extent the SLLMWITQCFL 157-167 peptide, but not the less immunogenic QLSLLMWIT 155-163 peptide (Fig. 6A) . The results in the HHD mice parallel the epitope specificity observed in NY-ESO-1-specific CD8
ϩ T cells isolated from HLA-A2 ϩ individuals with NY-ESO-1-expressing tumors. Furthermore, all of the mice (five of five) immunized with the NY-ESO-1 vaccine generated CD8 ϩ T cells capable of killing the SLLMWITQC 157-165 -pulsed target cells, whereas mice vaccinated with NY-ESO-1 protein alone failed to generate such CD8 ϩ T cells (Fig. 6B) . Furthermore, HHD mice immunized with the NY-ESO-1 vaccine (but not NY-ESO-1 protein alone) generated SLLMWITQC 157-165 -specific CD8 ϩ T cells that secreted IFN-␥ (Fig. 6C) . Together, these data demonstrate that the NY-ESO-1 vaccine was a potent inducer of HLA-A2-restricted CD8 ϩ T-cell responses in mice. HHD-derived CD8 ϩ T cells from mice immunized with the NY-ESO-1 vaccine (but not those immunized with NY-ESO-1 protein alone) were examined for their capacity to kill human tumor cell lines. These CD8 ϩ T cells efficiently killed the HLA-A2
ϩ NY-ESO-1 2ϩ melanoma line SK-Mel-37, but not HLA-A2
Ϫ or NY-ESO-1 Ϫ tumor lines, or the AO2b tumor line (low NY-ESO-1 expression by IHC; Fig. 7 ). These results demonstrate that Fig. 8 demonstrates that B16 melanoma cells expressing NY-ESO-1 grew rapidly in mock buffer-treated and ISCOMATRIX adjuvant-treated control animals, with tumors reaching Ͼ120 mm 2 by day 22, at which time mice were sacrificed (Fig. 8) . In contrast, mice immunized with the NY-ESO-1 vaccine were all tumor free on day 22, and by 120 days, one-half of these mice were still without tumor (Fig. 8) . This indicates that vaccination of naïve mice with the NY-ESO-1 vaccine induces a potent NY-ESO-1-specific immune response in vivo sufficient to regress NY-ESO-1-expressing B16 melanoma cells.
DISCUSSION
Analysis of successful immune responses against viral pathogens can provide a useful framework for designing vaccines for effective T-cell immune responses against cancer. Strategies that can convert innocuous tumor-expressed antigens into ones perceived as life threatening and, therefore, immunogenic, represent one of the many challenges facing cancer vaccine-based immunotherapy. The development of effective cancer vaccines that are not patient specific has been hampered by the paucity of vaccines that are capable of safely and effectively inducing CD8 ϩ T cells in humans. Furthermore, the ability to sustain anticancer CD8 ϩ T cells through repeated immunizations is likely to emerge as an important feature of therapeutic anticancer vaccines (19, 20, 33) . Thus, although viral vectors such as replication-defective poxvirus vaccine vectors have been tested with some success (34), these cannot be used repeatedly because of the induction of anti-vector neutralizing antibodies. DNA vaccines are also being developed as anticancer vaccine modalities but, to date, have shown limited potency; and, thus, improvements are likely to be required before this technology becomes effective against cancer (35) . Adjuvant systems that are capable of inducing CD8 ϩ T-cell responses against tumor antigens provide an attractive alternative strategy.
The cancer-testes antigen NY-ESO-1 represents one of the more promising tumor-associated targets for vaccine-based immunotherapy of cancer. Unlike several other tumor-associated antigens, NY-ESO-1 is relatively immunogenic in cancer patients, with both humoral and T-cell responses generated either spontaneously or after vaccination with peptides (4, 12) . The data presented here illustrate that associating the ISCOMATRIX adjuvant with a recombinant NY-ESO-1 protein to form an NY-ESO-1 vaccine results in a potent anticancer vaccine that induces more effective humoral and CD8
ϩ CTL responses in vivo than does nonadjuvanted NY-ESO-1 protein alone. In mice, the NY-ESO-1 vaccine induced strong IFN-␥-biased responses, resulting in both IgG1 and IgG2a antibodies and in the generation of potent CD8 ϩ T cells capable of killing HLA-A2
ϩ NY-ESO-1-expressing human tumors in vitro, as well as protecting mice against challenge with NY-ESO-1-expressing B16 melanoma cells. The NY-ESO-1 vaccine potently induced CD8 ϩ T-cell responses in HLA-A2-transgenic HHD mice, similar to those seen after immunization with other CD8 ϩ T-cell-inducing vaccine modalities, such as live recombinant vaccinia virus (28, 36) . Furthermore, the presence of the ISCOMATRIX adjuvant significantly enhanced the immunogenicity of NY-ESO-1 protein, because NY-ESO-1 protein alone generated relatively poor responses in vivo. The ability of ISCOMA-TRIX adjuvant to induce antigen-specific CD8 ϩ T-cell responses capable of rejecting antigen-expressing tumors was also demonstrated using the ovalbumin (OVA) antigen model. In that study, the OVA-ISCOMATRIX vaccine induced rejection of OVAexpressing EG7 tumors, OVA-expressing-B16 melanoma, and OVA-expressing Lewis Lung carcinoma in mice (24) . Furthermore, in all of these tumor models, only the OVA-expressing tumors, but not the parental tumors implanted in the opposing flank, were rejected, indicating that ISCOMATRIX vaccines induce antigen-specific immunity. Finally, class II MHCϪ/Ϫ mice, immunized with the OVA-ISCOMATRIX vaccine, efficiently generated antitumor CD8
ϩ CTLs in the absence of CD4 ϩ T-cell help (24) .
The NY-ESO-1 vaccine was efficiently taken up by immature human MoDCs, and this appeared to be initiated by the binding of the NY-ESO-1 vaccine onto the surface membrane of DCs. It is unclear whether this binding required the use of specific receptormediated mechanisms or simply binding via hydrophobic interactions between the DC lipid membrane and the lipids of the ISCO-MATRIX adjuvant. Interestingly, surface-associated NY-ESO-1 vaccine steadily decreased over time, with most of the vaccine readily detectable in the cytosol by 3 h, suggesting that surface membrane turnover may represent one mechanism of vaccine incorporation into DCs for processing. NY-ESO-1 vaccine did not induce MoDC maturation, unlike known inducers of MoDC mat- Fig. 8 The NY-ESO-1/ISCOMATRIX adjuvant (NY-ESO-1/IMX) vaccine protects mice from challenge with B16 melanoma expressing NY-ESO-1. C57BL/6 mice (n ϭ 6/group) were vaccinated with the NY-ESO-1/IMX vaccine or with PBS buffer alone (buffer control group) or with IMX adjuvant alone (adjuvant control group) and were then challenged with B16 melanoma cell line transfected with NY-ESO-1. Tumor area was measured at the indicated times, and mice were sacrificed when tumors exceeded 180 mm 2 .
